Journal
CANCER RESEARCH
Volume 69, Issue 8, Pages 3579-3588Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-3701
Keywords
-
Categories
Funding
- IWMF 2S
- MMRF Fellowship
- Mary-Lou Kurtz Fellowship [R01-AG020686, CA83724-01, SPORE P50-CA100707-01]
- National Cancer Institute [P01-CA62242]
- Donaldson Charitable Trust Fund
- International Waldenstrom Macroglobulinemia Foundation
- Damon Runyon Cancer Research Fund
Ask authors/readers for more resources
Waldenstrom's macroglobulinemia (WM) is a distinct clinicobiological entity defined as a B-cell neoplasm characterized by a lymphoplasmacytic infiltrate in bone marrow (BM) and IgM paraprotein production. Cytogenetic analyses were historically limited by difficulty in obtaining tumor metaphases, and the genetic basis of the disease remains poorly defined. Here, we performed a comprehensive analysis in 42 WM patients by using a high-resolution, array-based comparative genomic hybridization approach to unravel the genetic mechanisms associated with WM pathogenesis. Overall, 83% of cases have chromosomal abnormalities, with a median of three abnormalities per patient. Gain of 61) was the second most common abnormality (17%), and its presence was always concomitant with 6q loss. A minimal deleted region, including MIRN15A and MIRN16-1, was delineated on 13q14 in 10% of patients. Of interest, we reported biallelic deletions and/or inactivating mutations with uniparental disomy in tumor necrosis factor (TNF) receptor-associated factor 3 and TNF alpha-induced protein 3, two negative regulators of the nuclear factor-kappa B (NF-kappa B) signaling pathway. Furthermore, we confirmed the association between TRAF3 inactivation and increased transcriptional activity of NF-kappa B target genes. Mutational activation of the NF-kappa B pathway, which is normally activated by ligand receptor interactions within the BM microenvironment, highlights its biological importance, and suggests a therapeutic role for inhibitors of NF-kappa B pathway activation in the treatment of WM. [Cancer Res 2009;69(8):3579-88]
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available